Get informed when a big investor buys or sells
+ FollowOvervalued by 82.4% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $67.41 Million |
|---|---|
| Enterprise Value | $62.59 Million |
| Earnings per Share | $-0.01 |
| Beta | 1.81 |
| Outstanding Shares | 703,662,758 |
| P/E Ratio | -7.5 |
|---|---|
| PEG | 68.63 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.27 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Ki...